JP2008526773A - ベクロメタゾンジプロピオネート及びプレドニゾンでの、移植片対宿主病及び白血病の治療 - Google Patents
ベクロメタゾンジプロピオネート及びプレドニゾンでの、移植片対宿主病及び白血病の治療 Download PDFInfo
- Publication number
- JP2008526773A JP2008526773A JP2007549693A JP2007549693A JP2008526773A JP 2008526773 A JP2008526773 A JP 2008526773A JP 2007549693 A JP2007549693 A JP 2007549693A JP 2007549693 A JP2007549693 A JP 2007549693A JP 2008526773 A JP2008526773 A JP 2008526773A
- Authority
- JP
- Japan
- Prior art keywords
- bdp
- day
- days
- treatment
- gvhd
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000024908 graft versus host disease Diseases 0.000 title claims abstract description 88
- 238000011282 treatment Methods 0.000 title claims abstract description 68
- 229960004618 prednisone Drugs 0.000 title claims abstract description 61
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 title claims abstract description 61
- 208000032839 leukemia Diseases 0.000 title claims abstract description 17
- 208000009329 Graft vs Host Disease Diseases 0.000 title claims description 82
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 title description 104
- 229950000210 beclometasone dipropionate Drugs 0.000 title description 8
- 238000000034 method Methods 0.000 claims abstract description 65
- 238000002054 transplantation Methods 0.000 claims abstract description 39
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims abstract description 30
- 239000000203 mixture Substances 0.000 claims abstract description 21
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims abstract description 20
- 238000009472 formulation Methods 0.000 claims abstract description 17
- 238000011260 co-administration Methods 0.000 claims abstract description 8
- 239000003246 corticosteroid Substances 0.000 claims description 40
- 230000000694 effects Effects 0.000 claims description 29
- 239000002775 capsule Substances 0.000 claims description 27
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 claims description 27
- 210000004027 cell Anatomy 0.000 claims description 19
- 229960001334 corticosteroids Drugs 0.000 claims description 19
- 230000000735 allogeneic effect Effects 0.000 claims description 18
- 210000004369 blood Anatomy 0.000 claims description 18
- 239000008280 blood Substances 0.000 claims description 18
- 206010028980 Neoplasm Diseases 0.000 claims description 17
- 239000006187 pill Substances 0.000 claims description 15
- 238000010322 bone marrow transplantation Methods 0.000 claims description 14
- 239000004005 microsphere Substances 0.000 claims description 14
- 230000009885 systemic effect Effects 0.000 claims description 14
- 201000011510 cancer Diseases 0.000 claims description 13
- 210000000813 small intestine Anatomy 0.000 claims description 13
- 210000001185 bone marrow Anatomy 0.000 claims description 12
- 239000003018 immunosuppressive agent Substances 0.000 claims description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 11
- 201000010099 disease Diseases 0.000 claims description 10
- -1 halcinoside Chemical compound 0.000 claims description 10
- 210000004185 liver Anatomy 0.000 claims description 10
- 210000001072 colon Anatomy 0.000 claims description 9
- 239000000839 emulsion Substances 0.000 claims description 9
- 229940124589 immunosuppressive drug Drugs 0.000 claims description 9
- OHYGPBKGZGRQKT-XGQKBEPLSA-N [(8s,9r,10s,11s,13s,14s,16s,17r)-9-chloro-11-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] propanoate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(OC(=O)CC)[C@@]1(C)C[C@@H]2O OHYGPBKGZGRQKT-XGQKBEPLSA-N 0.000 claims description 8
- 229940006003 beclomethasone 17-monopropionate Drugs 0.000 claims description 8
- 210000002784 stomach Anatomy 0.000 claims description 8
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 6
- 108010036949 Cyclosporine Proteins 0.000 claims description 6
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 6
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims description 6
- 229960001265 ciclosporin Drugs 0.000 claims description 6
- 229930182912 cyclosporin Natural products 0.000 claims description 6
- 229960000485 methotrexate Drugs 0.000 claims description 6
- 229960001967 tacrolimus Drugs 0.000 claims description 6
- 102000006395 Globulins Human genes 0.000 claims description 5
- 108010044091 Globulins Proteins 0.000 claims description 5
- 241001465754 Metazoa Species 0.000 claims description 5
- 230000000781 anti-lymphocytic effect Effects 0.000 claims description 5
- 230000007423 decrease Effects 0.000 claims description 5
- 230000003247 decreasing effect Effects 0.000 claims description 5
- 230000001506 immunosuppresive effect Effects 0.000 claims description 5
- 230000002637 immunotoxin Effects 0.000 claims description 5
- 229940051026 immunotoxin Drugs 0.000 claims description 5
- 239000002596 immunotoxin Substances 0.000 claims description 5
- 231100000608 immunotoxin Toxicity 0.000 claims description 5
- 230000037396 body weight Effects 0.000 claims description 4
- 210000005095 gastrointestinal system Anatomy 0.000 claims description 4
- 229960005205 prednisolone Drugs 0.000 claims description 4
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 4
- 206010068051 Chimerism Diseases 0.000 claims description 3
- 229960004703 clobetasol propionate Drugs 0.000 claims description 3
- CBGUOGMQLZIXBE-XGQKBEPLSA-N clobetasol propionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CCl)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CBGUOGMQLZIXBE-XGQKBEPLSA-N 0.000 claims description 3
- 229960000676 flunisolide Drugs 0.000 claims description 3
- 229960000289 fluticasone propionate Drugs 0.000 claims description 3
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 claims description 3
- 229960003444 immunosuppressant agent Drugs 0.000 claims description 3
- 229960002744 mometasone furoate Drugs 0.000 claims description 3
- WOFMFGQZHJDGCX-ZULDAHANSA-N mometasone furoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(Cl)[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)C(=O)CCl)C(=O)C1=CC=CO1 WOFMFGQZHJDGCX-ZULDAHANSA-N 0.000 claims description 3
- 230000001737 promoting effect Effects 0.000 claims description 3
- MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 claims description 3
- 238000011476 stem cell transplantation Methods 0.000 claims description 3
- 229960002117 triamcinolone acetonide Drugs 0.000 claims description 3
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 claims description 3
- 229950008396 ulobetasol propionate Drugs 0.000 claims description 3
- BDSYKGHYMJNPAB-LICBFIPMSA-N ulobetasol propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H](C)[C@@](C(=O)CCl)(OC(=O)CC)[C@@]2(C)C[C@@H]1O BDSYKGHYMJNPAB-LICBFIPMSA-N 0.000 claims description 3
- 230000001861 immunosuppressant effect Effects 0.000 claims 2
- 230000001024 immunotherapeutic effect Effects 0.000 claims 1
- 230000009467 reduction Effects 0.000 abstract description 7
- 230000000977 initiatory effect Effects 0.000 abstract description 3
- 206010066901 Treatment failure Diseases 0.000 description 36
- 239000003814 drug Substances 0.000 description 34
- 229940079593 drug Drugs 0.000 description 32
- 208000004605 Persistent Truncus Arteriosus Diseases 0.000 description 25
- 208000037258 Truncus arteriosus Diseases 0.000 description 25
- 230000002496 gastric effect Effects 0.000 description 24
- 208000024891 symptom Diseases 0.000 description 24
- 229940068196 placebo Drugs 0.000 description 19
- 239000000902 placebo Substances 0.000 description 19
- 238000012360 testing method Methods 0.000 description 17
- 230000000968 intestinal effect Effects 0.000 description 16
- 239000002552 dosage form Substances 0.000 description 15
- 238000004458 analytical method Methods 0.000 description 13
- 230000001186 cumulative effect Effects 0.000 description 10
- 238000001990 intravenous administration Methods 0.000 description 10
- 210000000936 intestine Anatomy 0.000 description 9
- 230000004044 response Effects 0.000 description 9
- 229940092705 beclomethasone Drugs 0.000 description 8
- 210000001035 gastrointestinal tract Anatomy 0.000 description 8
- 230000004179 hypothalamic–pituitary–adrenal axis Effects 0.000 description 8
- 230000002411 adverse Effects 0.000 description 7
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 6
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 6
- 206010025323 Lymphomas Diseases 0.000 description 6
- 206010035226 Plasma cell myeloma Diseases 0.000 description 6
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 6
- 238000000576 coating method Methods 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 6
- 201000000050 myeloid neoplasm Diseases 0.000 description 6
- 230000036470 plasma concentration Effects 0.000 description 6
- 230000001629 suppression Effects 0.000 description 6
- 230000000699 topical effect Effects 0.000 description 6
- 206010012735 Diarrhoea Diseases 0.000 description 5
- 239000011248 coating agent Substances 0.000 description 5
- 230000034994 death Effects 0.000 description 5
- 231100000517 death Toxicity 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 239000000275 Adrenocorticotropic Hormone Substances 0.000 description 4
- 102400000739 Corticotropin Human genes 0.000 description 4
- 101800000414 Corticotropin Proteins 0.000 description 4
- 230000001919 adrenal effect Effects 0.000 description 4
- 238000001574 biopsy Methods 0.000 description 4
- 210000000601 blood cell Anatomy 0.000 description 4
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 4
- 229960000258 corticotropin Drugs 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 238000011866 long-term treatment Methods 0.000 description 4
- 230000003211 malignant effect Effects 0.000 description 4
- 210000000130 stem cell Anatomy 0.000 description 4
- 150000003431 steroids Chemical class 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- 238000012384 transportation and delivery Methods 0.000 description 4
- 208000010201 Exanthema Diseases 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 3
- 206010028813 Nausea Diseases 0.000 description 3
- 206010047700 Vomiting Diseases 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 239000002702 enteric coating Substances 0.000 description 3
- 238000009505 enteric coating Methods 0.000 description 3
- 201000005884 exanthem Diseases 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 102000054766 genetic haplotypes Human genes 0.000 description 3
- 229960000890 hydrocortisone Drugs 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229960004584 methylprednisolone Drugs 0.000 description 3
- 230000008693 nausea Effects 0.000 description 3
- 210000005259 peripheral blood Anatomy 0.000 description 3
- 239000011886 peripheral blood Substances 0.000 description 3
- 229940096335 prednisone 1 mg Drugs 0.000 description 3
- 206010037844 rash Diseases 0.000 description 3
- 230000004043 responsiveness Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 206010001367 Adrenal insufficiency Diseases 0.000 description 2
- 229920001661 Chitosan Polymers 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 206010022678 Intestinal infections Diseases 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 208000017515 adrenocortical insufficiency Diseases 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 208000022531 anorexia Diseases 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 229920001400 block copolymer Polymers 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 150000005690 diesters Chemical class 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 210000003238 esophagus Anatomy 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000007897 gelcap Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000000017 hydrogel Substances 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 238000002650 immunosuppressive therapy Methods 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 210000005228 liver tissue Anatomy 0.000 description 2
- 238000001325 log-rank test Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- 239000000693 micelle Substances 0.000 description 2
- 238000009522 phase III clinical trial Methods 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 229920001451 polypropylene glycol Polymers 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000011272 standard treatment Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000007910 systemic administration Methods 0.000 description 2
- 230000001839 systemic circulation Effects 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- 229920003067 (meth)acrylic acid ester copolymer Polymers 0.000 description 1
- RWHRFHQRVDUPIK-UHFFFAOYSA-N 50867-57-7 Chemical compound CC(=C)C(O)=O.CC(=C)C(O)=O RWHRFHQRVDUPIK-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- SPNQRCTZKIBOAX-UHFFFAOYSA-N Butralin Chemical compound CCC(C)NC1=C([N+]([O-])=O)C=C(C(C)(C)C)C=C1[N+]([O-])=O SPNQRCTZKIBOAX-UHFFFAOYSA-N 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 206010011655 Cushingoid Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 229920003134 Eudragit® polymer Polymers 0.000 description 1
- 238000000729 Fisher's exact test Methods 0.000 description 1
- 206010064147 Gastrointestinal inflammation Diseases 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000034486 Multi-organ failure Diseases 0.000 description 1
- 208000010718 Multiple Organ Failure Diseases 0.000 description 1
- 208000010428 Muscle Weakness Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 206010058803 Oesophageal infection Diseases 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 206010048685 Oral infection Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920000805 Polyaspartic acid Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108010020346 Polyglutamic Acid Proteins 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 206010053879 Sepsis syndrome Diseases 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 208000035286 Spontaneous Remission Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 description 1
- 208000025371 Taste disease Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 238000001793 Wilcoxon signed-rank test Methods 0.000 description 1
- GAMPNQJDUFQVQO-UHFFFAOYSA-N acetic acid;phthalic acid Chemical compound CC(O)=O.OC(=O)C1=CC=CC=C1C(O)=O GAMPNQJDUFQVQO-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 208000024340 acute graft versus host disease Diseases 0.000 description 1
- 230000003474 anti-emetic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940125683 antiemetic agent Drugs 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229940045110 chitosan Drugs 0.000 description 1
- 235000017803 cinnamon Nutrition 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 230000002254 contraceptive effect Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940026692 decadron Drugs 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 231100000722 genetic damage Toxicity 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000008073 immune recognition Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 235000019656 metallic taste Nutrition 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000004001 molecular interaction Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 1
- RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 description 1
- 229960004866 mycophenolate mofetil Drugs 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 239000007968 orange flavor Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 210000003300 oropharynx Anatomy 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000032696 parturition Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 238000013439 planning Methods 0.000 description 1
- 229920000233 poly(alkylene oxides) Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 108010064470 polyaspartate Proteins 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920002643 polyglutamic acid Polymers 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 238000007390 skin biopsy Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 229940125379 topical corticosteroid Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 210000003606 umbilical vein Anatomy 0.000 description 1
- 230000004222 uncontrolled growth Effects 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Transplantation (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US64017804P | 2004-12-30 | 2004-12-30 | |
| PCT/US2005/047666 WO2006072093A2 (en) | 2004-12-30 | 2005-12-30 | Treatment of graft-versus-host disease and leukemia with beclomethasone dipropionate and prednisone |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008526773A true JP2008526773A (ja) | 2008-07-24 |
| JP2008526773A5 JP2008526773A5 (enExample) | 2009-06-04 |
Family
ID=36615583
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007549693A Pending JP2008526773A (ja) | 2004-12-30 | 2005-12-30 | ベクロメタゾンジプロピオネート及びプレドニゾンでの、移植片対宿主病及び白血病の治療 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20060252735A1 (enExample) |
| EP (1) | EP1830857B1 (enExample) |
| JP (1) | JP2008526773A (enExample) |
| KR (1) | KR20070089701A (enExample) |
| CN (2) | CN102218070A (enExample) |
| AT (1) | ATE481102T1 (enExample) |
| AU (1) | AU2005321826B2 (enExample) |
| CA (1) | CA2583244A1 (enExample) |
| DE (1) | DE602005023655D1 (enExample) |
| DK (1) | DK1830857T3 (enExample) |
| IL (1) | IL182462A0 (enExample) |
| NZ (1) | NZ554326A (enExample) |
| WO (1) | WO2006072093A2 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023506779A (ja) * | 2019-12-09 | 2023-02-20 | シンダックス ファーマシューティカルズ， インコーポレイテッド | 慢性移植片対宿主病の処置用抗体 |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090143328A1 (en) * | 2001-08-13 | 2009-06-04 | Mcdonald George | Method of Treating Cancer by Administration of Topical Active Corticosteroids |
| AU2009333538B2 (en) * | 2008-12-08 | 2014-09-11 | Soligenix, Inc. | Topically active steroids for use in radiation and chemotherapeutics injury |
| US20170209447A1 (en) * | 2014-08-07 | 2017-07-27 | Nitor Therapeutics | Use of PNP Inhibitor to Treat Relapse of Malignancy after Hematopoietic Stem Cell Transplant |
| CN106236736A (zh) * | 2016-09-26 | 2016-12-21 | 安徽省逸欣铭医药科技有限公司 | 二丙酸倍氯米松肠溶缓释片及其制备方法 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030032631A1 (en) * | 2001-08-13 | 2003-02-13 | Mcdonald George B. | Method of treatment of cancer by controlling graft-versus-leukemia using topical active corticosteriods |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6096728A (en) * | 1996-02-09 | 2000-08-01 | Amgen Inc. | Composition and method for treating inflammatory diseases |
| US5747474A (en) * | 1996-07-29 | 1998-05-05 | Immune Modulation, Inc. | Immunosuppression by administration of N6,N6 -disubstituted cAMP's, analogues thereof, and related nucleosides |
| US6096731A (en) * | 1998-06-24 | 2000-08-01 | Institute For Drug Research, Inc. | Method for preventing tissue damage associated with graft-versus-host or host-versus-graft disease following transplantation |
| US20020086857A1 (en) * | 2000-09-15 | 2002-07-04 | Mcdonald George B. | Method of long-term treatment of graft-versus-host disease using topical active corticosterioids |
| IL157921A0 (en) * | 2001-03-15 | 2004-03-28 | Enteron Pharmaceuticals Inc | Method of treating inflammatory disorders of the gastrointestinal tract using topical active corticosteroids |
| JP4014912B2 (ja) * | 2001-09-28 | 2007-11-28 | 株式会社ルネサステクノロジ | 半導体装置 |
-
2005
- 2005-12-30 AT AT05856121T patent/ATE481102T1/de not_active IP Right Cessation
- 2005-12-30 JP JP2007549693A patent/JP2008526773A/ja active Pending
- 2005-12-30 CA CA002583244A patent/CA2583244A1/en not_active Abandoned
- 2005-12-30 KR KR1020077013835A patent/KR20070089701A/ko not_active Ceased
- 2005-12-30 DK DK05856121.8T patent/DK1830857T3/da active
- 2005-12-30 WO PCT/US2005/047666 patent/WO2006072093A2/en not_active Ceased
- 2005-12-30 EP EP05856121A patent/EP1830857B1/en not_active Expired - Lifetime
- 2005-12-30 CN CN2011101121156A patent/CN102218070A/zh active Pending
- 2005-12-30 US US11/320,564 patent/US20060252735A1/en not_active Abandoned
- 2005-12-30 NZ NZ554326A patent/NZ554326A/en not_active IP Right Cessation
- 2005-12-30 AU AU2005321826A patent/AU2005321826B2/en not_active Ceased
- 2005-12-30 CN CN2005800393955A patent/CN101060848B/zh not_active Expired - Fee Related
- 2005-12-30 DE DE602005023655T patent/DE602005023655D1/de active Active
-
2007
- 2007-04-11 IL IL182462A patent/IL182462A0/en unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030032631A1 (en) * | 2001-08-13 | 2003-02-13 | Mcdonald George B. | Method of treatment of cancer by controlling graft-versus-leukemia using topical active corticosteriods |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023506779A (ja) * | 2019-12-09 | 2023-02-20 | シンダックス ファーマシューティカルズ， インコーポレイテッド | 慢性移植片対宿主病の処置用抗体 |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2583244A1 (en) | 2006-07-06 |
| EP1830857B1 (en) | 2010-09-15 |
| AU2005321826B2 (en) | 2012-03-15 |
| DK1830857T3 (da) | 2011-02-07 |
| NZ554326A (en) | 2010-10-29 |
| CN102218070A (zh) | 2011-10-19 |
| WO2006072093A3 (en) | 2007-03-22 |
| IL182462A0 (en) | 2008-04-13 |
| EP1830857A4 (en) | 2008-02-27 |
| US20060252735A1 (en) | 2006-11-09 |
| WO2006072093A2 (en) | 2006-07-06 |
| CN101060848A (zh) | 2007-10-24 |
| AU2005321826A1 (en) | 2006-07-06 |
| EP1830857A2 (en) | 2007-09-12 |
| ATE481102T1 (de) | 2010-10-15 |
| CN101060848B (zh) | 2011-06-22 |
| DE602005023655D1 (de) | 2010-10-28 |
| KR20070089701A (ko) | 2007-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7407880B2 (ja) | 前立腺癌の併用療法 | |
| López-Sanromán et al. | Reviewing the therapeutic role of budesonide in Crohn's disease | |
| US9889100B2 (en) | Cannabidiol for treatment of severe and refractory graft-versus-host disease | |
| Martin et al. | Evaluation of oral beclomethasone dipropionate for prevention of acute graft-versus-host disease | |
| US6096731A (en) | Method for preventing tissue damage associated with graft-versus-host or host-versus-graft disease following transplantation | |
| MX2009001248A (es) | Tratamiento con glucocorticoide de liberacion prolongada de enfermedad reumatoide. | |
| JP2008526773A (ja) | ベクロメタゾンジプロピオネート及びプレドニゾンでの、移植片対宿主病及び白血病の治療 | |
| JP4326696B2 (ja) | 糸球体腎炎の治療のための方法および手段 | |
| US6239120B1 (en) | Method and means for treating glomerulonephritis | |
| US20100184732A1 (en) | Method of long-term treatment of graft-versus-host disease using topical active corticosteroids | |
| JP2021532080A (ja) | 肝疾患の掻痒症状の治療 | |
| CN112274511B (zh) | 用于治疗移植物抗宿主病的喹啉衍生物 | |
| Katz | Update in medical therapy in inflammatory bowel disease: a clinician’s view | |
| US20030032631A1 (en) | Method of treatment of cancer by controlling graft-versus-leukemia using topical active corticosteriods | |
| US20020086857A1 (en) | Method of long-term treatment of graft-versus-host disease using topical active corticosterioids | |
| CN118043051A (zh) | 用于治疗或预防抗宿主病的吡咯并六元杂芳物 | |
| CA2413883C (en) | Method for preventing tissue damage associated with graft-versus-host or host-versus-graft disease following transplantation | |
| HK40092155A (en) | Combination therapy for prostate cancer | |
| US20220265574A1 (en) | Methods of using cannabidiol and a steroid | |
| CN117440814A (zh) | 用于治疗扁平苔藓的外用鲁索替尼 | |
| US20140328929A1 (en) | Method of Preventing Acute Graft-Versus-Host Disease using Oral Beclomethasone Dipropionate | |
| Man | Crohn’s Disease Local Retrospective and Future Prospective |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20081226 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090415 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110816 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20111116 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20120420 |